ELT Sight has acquired the IP and assets for MLase’s excimer ophthalmic laser system for glaucoma surgery, according to a press release.
The company expects to expand marketing activities of the ExTra ELT laser system and disposable applicator in Europe, where it received CE certification in 2014, and initiate clinical studies in the United States in early 2020.
“There is a growing need for new solutions to address glaucoma, a global health challenge expected to affect 80 million people worldwide in 2020. Clinical studies in Europe have demonstrated that the ExTra ELT laser system offers patients with glaucoma an implant-free choice to lower eye pressure,” ELT Sight CEO Elliott Friedman said in the release. “Our hope is to simultaneously ramp up marketing activities in Europe while conducting clinical trials in the United States early next year.”